184 related articles for article (PubMed ID: 18587443)
1. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.
Shiomi M; Yamada S; Amano Y; Nishimoto T; Ito T
Br J Pharmacol; 2008 Jul; 154(5):949-57. PubMed ID: 18587443
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
[TBL] [Abstract][Full Text] [Related]
3. Emerging lipid-lowering drugs: squalene synthase inhibitors.
Elsayed RK; Evans JD
Expert Opin Emerg Drugs; 2008 Jun; 13(2):309-22. PubMed ID: 18537523
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
Amano Y; Nishimoto T; Tozawa Ri; Ishikawa E; Imura Y; Sugiyama Y
Eur J Pharmacol; 2003 Apr; 466(1-2):155-61. PubMed ID: 12679152
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y
Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864
[TBL] [Abstract][Full Text] [Related]
6. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia.
Stein EA; Bays H; O'Brien D; Pedicano J; Piper E; Spezzi A
Circulation; 2011 May; 123(18):1974-85. PubMed ID: 21518985
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S; Frishman WH
Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
[TBL] [Abstract][Full Text] [Related]
8. Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation.
Rimondi E; Valencic E; Tommasini A; Secchiero P; Melloni E; Marcuzzi A
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680069
[TBL] [Abstract][Full Text] [Related]
9. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H
Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728
[TBL] [Abstract][Full Text] [Related]
10. Morphological features of coronary plaques in WHHLMI rabbits (Oryctolagus cuniculus), an animal model for familial hypercholesterolemia.
Yamada S; Koike T; Nakagawa T; Kuniyoshi N; Ying Y; Itabe H; Yamashita A; Asada Y; Shiomi M
Exp Anim; 2017 May; 66(2):145-157. PubMed ID: 28025424
[TBL] [Abstract][Full Text] [Related]
11. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species.
Ugawa T; Kakuta H; Moritani H; Matsuda K; Ishihara T; Yamaguchi M; Naganuma S; Iizumi Y; Shikama H
Br J Pharmacol; 2000 Sep; 131(1):63-70. PubMed ID: 10960070
[TBL] [Abstract][Full Text] [Related]
12. beta-VLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits.
Holvoet P; Collen D
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2376-82. PubMed ID: 9409204
[TBL] [Abstract][Full Text] [Related]
13. Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?
Liao JK
Circulation; 2011 May; 123(18):1925-8. PubMed ID: 21518979
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.
Ebihara T; Teshima K; Kondo T; Tagawa Y; Moriwaki T; Asahi S
Drug Res (Stuttg); 2016 Jun; 66(6):287-92. PubMed ID: 26839207
[TBL] [Abstract][Full Text] [Related]
15. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice.
Marcuzzi A; Loganes C; Celeghini C; Kleiner G
Curr Med Chem; 2018; 25(24):2783-2796. PubMed ID: 28901277
[TBL] [Abstract][Full Text] [Related]
16. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors.
Tavridou A; Manolopoulos VG
Curr Pharm Des; 2009; 15(27):3167-78. PubMed ID: 19754389
[TBL] [Abstract][Full Text] [Related]
17. Squalene synthase inhibition: a novel target for the management of dyslipidemia.
Davidson MH
Curr Atheroscler Rep; 2007 Jan; 9(1):78-80. PubMed ID: 17169251
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking studies to map the binding site of squalene synthase inhibitors on dehydrosqualene synthase of Staphylococcus aureus.
Kahlon AK; Roy S; Sharma A
J Biomol Struct Dyn; 2010 Oct; 28(2):201-10. PubMed ID: 20645653
[TBL] [Abstract][Full Text] [Related]
19. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
[TBL] [Abstract][Full Text] [Related]
20. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Watanabe Y; Ito T; Shiomi M; Tsujita Y; Kuroda M; Arai M; Fukami M; Tamura A
Biochim Biophys Acta; 1988 Jun; 960(3):294-302. PubMed ID: 3132979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
